Biotech stock’s

After those absolutely miserable month’s of selloff, the biotechnology sector was affected as well and  there wasn’t a lot of  potential for upside offer’s.With some major biotech indices we’ve register  losses of 35%-40% since July.However biotech stock’s still have a wealth of upside potential to offer,which makes sense considering that they’re involved in the science of bettering and lengthening human life, and humans. 



Here’s some example of biotech stock fund’s for considering to buy them.. 


iShares Nasdaq Biotechnology ETF (IBB)

The (IBB) is the market’s largest biotech ETF by asset’s at $5.7 billion under management.Despite holding 190 stock’s, the lion’s share of IBB is held among the five stock’s – Celgene Corp. (CELG), Biogen (BIIB), Amgen (AMNG), Gilead Sciences (GILD) and Regeneron Pharma. (REGN), which combined make up 44% of the entire fund. While this provides many biotech stocks, the top-heavy (IBB) is more a play the “big five” as well as general bullishness on the whole sector.

Expenses: 0.48 percent, or $48 annually per $10,000 invested.



SPDR S&P Biotech ETF (XBI)

The XBI is an “equal-weight” fund, in which all stocks regardless of size are weighted equally as of each re-balancing — though the weight naturally changes depending on whether the stock gains or loses until the next re-balancing. So, larger biotechs such as AMGN and CELG have less impact on XBI than IBB, while smaller companies like AMAG Pharmaceuticals (AMAG) hold more sway. Thus, XBI is a way to better leverage the huge single-stock jumps you get from smaller biotech companies’ successful trials and FDA approvals.

Expenses: 0.35 percent



Loncar Cancer Immunotherapy ETF (CNCR)

The CNCR ETF is one of a few funds that look at a very specific subset of the biotech industry. In this case, CNCR “is made up of a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system.” This results in a small, equal-weighted group of 30 stocks leading this field forward, including familiar names like Celgene and other big players such as AstraZeneca (AZN), but also significant weights in smaller companies like Adaptimmune Therapeutics (ADAP) and Celyad (CYAD).

Expenses: 0.79 percent


ARK Invest Genomic Revolution Multi-Sector ETF (ARKG)

Ark Invest is an ETF provider that focuses on, in its own words, “disruptive innovation,” and has created a number of thoughtful funds to that end. ARKG is no different. This ETF invests in companies that incorporate genomics in their business, which produces natural fits like genome sequencing solutions firm Illumina (ILMN) and blood safety company Cerus Corp. (CERS). However, ARKG’s wide mandate also allows it to include ag giant Monsanto Co. (MON), which uses genetic engineering in its seeds, and even Nvidia Corp. (NVDA).

Expenses: 0.95 percent



BioShares Biotechnology Clinical Trials ETF (BBC)

Unlike BBP, which invests in companies that have approved products that can help drive revenues and profits, the BBC rolls the dice on trial-stage firms that have not yet gotten a green light from the FDA, and thus have no product sales. That means you’re looking at stocks with much smaller market capitalizations, much more volatility among the holdings and a huge dependency on clinical trial news. Top holdings include Inovio Pharmaceuticals (INO) and Aimmune Therapeutics (AIMT).

Expenses: 0.85 percent



J.Mason ♦